Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study

Michael J. Durkin, MD, MPH; S. Reza Jafarzadeh, DVM, MPVM, PhD; Kevin Hsueh, MD; Ya Haddy Sallah, MPH; Kiraat D. Munshi, PhD; Rochelle R. Henderson, PhD; Victoria J. Fraser, MD for the CDC Prevention Epicenters

OBJECTIVE. To characterize trends in outpatient antibiotic prescriptions in the United States

DESIGN. Retrospective ecological and temporal trend study evaluating outpatient antibiotic prescriptions from 2013 to 2015

SETTING. National administrative claims data from a pharmacy benefits manager PARTICIPANTS. Prescription pharmacy beneficiaries from Express Scripts Holding Company

MEASUREMENTS. Annual and seasonal percent change in antibiotic prescriptions

RESULTS. Approximately 98 million outpatient antibiotic prescriptions were filled by 39 million insurance beneficiaries during the 3-year study period. The most commonly prescribed antibiotics were azithromycin, amoxicillin, amoxicillin/clavulanate, ciprofloxacin, and cephalaxin. No significant changes in individual or overall annual antibiotic prescribing rates were found during the study period. Significant seasonal variation was observed, with antibiotics being 42% more likely to be prescribed during February than September (peak-to-trough ratio [PTTR], 1.42; 95% confidence interval [CI], 1.39–1.61). Similar seasonal trends were found for azithromycin (PTTR, 2.46; 95% CI, 2.44–3.47), amoxicillin (PTTR, 1.52; 95% CI, 1.42–1.89), and amoxicillin/clavulanate (PTTR, 1.78; 95% CI, 1.68–2.29).

CONCLUSIONS. This study demonstrates that annual national outpatient antibiotic prescribing practices remained unchanged during our study period. Furthermore, seasonal peaks in antibiotics generally used to treat viral upper respiratory tract infections remained unchanged during cold and influenza season. These results suggest that inappropriate prescribing of antibiotics remains widespread, despite the concurrent release of several guideline-based best practices intended to reduce inappropriate antibiotic consumption; however, further research linking national outpatient antibiotic prescriptions to associated medical conditions is needed to confirm these findings.

Infect Control Hosp Epidemiol 2018;1–6

The selective pressures of both inpatient and outpatient antibiotic use have contributed to the evolution of increasingly drug-resistant bacteria. The Centers for Disease Control and Prevention (CDC) recognizes multidrug-resistant organisms and infections, such as Clostridium difficile infection (CDI) and carbapenem-resistant Enterobacteriaceae (CRE), as urgent threats to the US healthcare system.1 It is estimated that the CDI alone causes 2,500,000 infections, 14,000 deaths, and $1 billion in excess medical costs per year. Furthermore, the first pan-resistant CRE isolate in the United States, mcr-1, was recently identified, ushering us into the "post-antibiotic era."2 Truly, more responsible management of antibiotic utilization is urgently needed to limit the development of antibiotic resistance.

Significant scrutiny has been placed on antibiotic utilization in hospitals. The CDC has proposed comparing and monitoring antibiotic utilization among hospitals using the standardized antimicrobial administration ratio.3 Furthermore, the Centers for Medicare and Medicaid Services has proposed a rule requiring all acute-care hospitals to have formal antibiotic stewardship programs to reduce inappropriate antibiotic use.4

Despite aggressive national action on inpatient antibiotic use, outpatient antibiotic utilization rates and appropriateness remains poorly studied. Conservative estimates suggest that up to 30% of outpatient antibiotic use among medical providers may be inappropriate.5 Mistreatment of viral respiratory tract conditions with antibiotics is particular concerning. For example, in one study, >70% of adult patients with pharyngitis were given an antibiotic prescription, while only 18% met treatment criteria for streptococcal pharyngitis.5 Sinusitis, also often a viral condition, was the number 1 medical condition associated with antibiotic prescriptions in a large national

Affiliations: 1. Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri; 2. Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; 3. Express Scripts Holding Company, St Louis, Missouri.

PREVIOUS PRESENTATION. A poster presentation of this data was presented at SHEA 2017 on March 31, 2017, in St Louis, Missouri.

Received October 23, 2017; accepted January 23, 2018

© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved. DOI: 10.1017/ice.2018.26
METHODOLOGY

Study Design and Data Source

This study is an ecological and temporal trend study involving retrospective analysis of outpatient antibiotic prescriptions from deidentified administrative claims data for the period between January 1, 2013, and December 31, 2015. Outpatient antibiotic prescription data were obtained for a sample of nearly 39 million insured members whose pharmacy benefits were managed by a large pharmacy benefit management company, Express Scripts Holding Company.

Study Variables

Antibiotic utilization was initially evaluated on an annual basis for the 3-year period from 2013 to 2015. All systemic outpatient antibiotics were summed per calendar year. Eligibility was not controlled for during the study period. Hence, prescription rates per 1,000 beneficiaries were calculated using midpoint values of beneficiaries for each calendar year. Antibiotic costs were calculated by summing individual members’ health insurance plan costs and out-of-pocket expenses. Costs per prescription were extracted and summed per calendar year and calculated as costs per 1,000 beneficiaries.

Data included total number of prescriptions, total number of prescribers, antibiotic name, number of antibiotic pills prescribed, date of prescription, cost of antibiotic prescription, and geographic location of prescriber by state. Prescription claims for members with missing or duplicate information were removed. In addition, reversed (unfilled) prescription claims were excluded from the analysis.

Analysis

Monthly prescription rates for all antibiotics were plotted for each of the 3 years examined in this study to visualize the seasonal variation. The 5 most commonly prescribed antibiotics in the database were plotted and assessed in a similar fashion. A seasonal pattern in health outcomes is often referred to events that happen with some regularity at fixed times or dates, or in distinct climatic periods; however, seasonality may not be specifically regular in its amplitude, timing, or shape.7

Seasonal variations in prescription counts were assessed by fitting log-linear Poisson regression models to monthly data. The magnitude of seasonal variations was quantified by peak-to-trough ratio (PTTR), which is interpreted as a relative risk with the trough month as the reference level.8 Unlike the estimators based on geometrical models that assume a single peak, 6 months subsequent to a trough, the estimator based on unadjusted Poisson regression provides flexibility in the pattern of seasonal variation and can adjust for the secular trend bias.

Overall temporal trends in antibiotics prescriptions were quantified and expressed as annual percent change through fitting linear regression models with autoregressive integrated moving average (ARIMA) errors to the natural logarithm of monthly rates.9 This allows accounting for the correlation of model errors over time (ie, autocorrelation) during the study period.10 Analyses for seasonality and trends were performed in R version 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria). All other statistics including descriptive analyses were computed using SAS version 9.4 (SAS Institute, Cary, NC). The Washington University Office of Human Research Protection approved this study.

RESULTS

Annual Antibiotic Prescription Trend

Approximately 98 million antibiotic prescriptions were filled during the 3-year study period from a sample of nearly 39 million insured members (Table 1). The mean number of prescriptions per 1,000 beneficiaries was 826 between 2013 and 2015, and this number ranged from 830 to 849 annually. There was a decrease in the antibiotic prescription rate between 2013 and 2014, followed by an increase in 2015. Although the average individual antibiotic costs per beneficiary were modest ($23 dollars per year), the overall costs in the cohort were enormous in our cohort, representing 840 million to nearly $1 billion annually.

The 5 most commonly prescribed antibiotics were azithromycin, amoxicillin, amoxicillin/clavulanate, ciprofloxacin, and cephalexin (Table 2). Linear regression estimates of temporal trends expressed as annual percent change in prescriptions demonstrated no statistically significant changes in prescribing rates during the 36-month study period for all antibiotics as well as the top 5 most commonly prescribed antibiotics (Table 2).

<table>
<thead>
<tr>
<th>Year</th>
<th>No. of Prescriptions, Millions</th>
<th>No. of Prescriptions per 1,000 Beneficiaries</th>
<th>Total Drug Costs, $</th>
<th>Cost per 1,000 Beneficiaries, $</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>29.95</td>
<td>829</td>
<td>902,658,788</td>
<td>24,994</td>
</tr>
<tr>
<td>2014</td>
<td>28.75</td>
<td>799</td>
<td>804,029,460</td>
<td>22,331</td>
</tr>
<tr>
<td>2015</td>
<td>28.98</td>
<td>851</td>
<td>764,731,899</td>
<td>22,460</td>
</tr>
<tr>
<td>Total</td>
<td>87.68</td>
<td>826</td>
<td>2,471,420,147</td>
<td>23,278</td>
</tr>
</tbody>
</table>
For example, usage of azithromycin, the most commonly prescribed (azithromycin, amoxicillin, and amoxicillin/clavulanate) had similar winter-peaking trends (Table 3 and Figure 1).

For example, usage of azithromycin, the most commonly prescribed medication in this study, increased by 146% in February compared to August (Table 3). Seasonal trends for the less commonly prescribed antibiotic medications, ciprofloxacin, and cephalaxin, however, were reversed, with the highest prescribing month in the summer and the lowest prescribing month in the winter (Table 3 and Figure 1). For example, usage of azithromycin, the most commonly prescribed medication in this study, increased by 146% in February compared to August (Table 3). Seasonal trends for the less commonly prescribed antibiotic medications, ciprofloxacin, and cephalaxin, however, were reversed, with the highest prescribing month in the summer and the lowest prescribing month in the winter (Table 3 and Figure 1). Furthermore, the seasonal variation in the usage of ciprofloxacin and cephalaxin was less pronounced; these medications had 15% and 22% increases in the peak month of August compared to the trough month of January, respectively (Table 3 and Figure 1).

**Seasonal Variation in Antibiotic Prescriptions**

The overall antibiotic prescription rate varied significantly by month (Figure 1) with a seasonal peak observed in February that was 42% higher than the trough in September (PTTR, 1.42; 95% confidence interval [CI], 1.39–1.61). The top 3 antibiotics prescribed (azithromycin, amoxicillin, and amoxicillin/clavulanate) had similar winter-peaking trends (Table 3 and Figure 1).

Some examples of more detailed interventions include antibiotic prescription benchmarking, audit and feedback, and education sessions.19,20

Seasonal variation in antibiotic prescribing has been previously reported in the United States,13,21 Europe,22,23 Canada,24 and Israel.25 In each of these studies, overall antibiotic use was higher during the winter months. The rate of increase ranged between 21% and 42%, with our study at the top of the range. The higher rate of macrolide antibiotic prescribing during the winter months has been linked to inappropriate antibiotic prescribing for viral infections.23–25 Previous investigators have suggested that spikes in antibiotic prescriptions during winter months may represent inappropriate treatment for viral conditions, which tend to occur more frequently during winter months.13,21,26–28
FIGURE 1. Monthly variation of rate of outpatient antibiotic use overall and stratified by the top 5 antibiotics. NOTE. Rx, prescription.
Many common bacterial infections also exhibit seasonal variation. For example, bloodstream infections,\textsuperscript{29,30} urinary tract infections,\textsuperscript{31} peritoneal dialysis infections,\textsuperscript{32} skin and soft-tissue infections,\textsuperscript{33} and surgical site infections\textsuperscript{34–36} are all more common during the summer months. However, \textit{Streptococcus pneumoniae}, community-acquired pneumonia, and methicillin-resistant \textit{Staphylococcus aureus} pneumonia tend to be more common during the winter months.\textsuperscript{37–40} Therefore, at least some of the peak in antibiotic prescribing is likely related to appropriate treatment of bacterial conditions. Not surprisingly, ciprofloxacin and cephalexin, common antibiotics used for urinary tract infections and skin and soft-tissue infections, were associated with higher antibiotic use during the summer months in our study. These findings are novel and have not been described previously in the literature. Furthermore, these findings also highlight that precautions must be taken not to overgeneralize when analyzing antibiotic use. For example, moxifloxacin and ciprofloxacin are both fluoroquinolone antibiotics; however, moxifloxacin is more frequently used for respiratory tract infections, while ciprofloxacin is used primarily for urinary tract infections. Classifying these 2 agents together could misrepresent the different seasonal patterns in the prescriptions of these medications and the infections they are used to treat.

This study has several limitations. First, this cohort represents only insured patients, so the results may not be generalizable to the entire US population, including uninsured individuals. However, our results were similar to those of larger studies estimating antibiotic prescribing for the entire United States.\textsuperscript{13} Second, medications are captured only when the claims are processed, so prescription claims that are not processed (eg, during instances when individuals chose to pay for inexpensive antibiotics out-of-pocket without using their insurance) were not captured. Therefore, our data likely underestimates overall antibiotic utilization in our cohort. Third, our analysis does not include any microbiology or medical claims data; thus, we were unable to adequately assess the appropriateness of each antibiotic prescribed or the comorbidities of patients who received antibiotics. For example, some antibiotic prescriptions written during the winter months were likely appropriate for conditions like Streptococcal and Staphylococcal pneumonia, which are more common during winter months as well. Fourth, the data set that we used did not contain information at an individual patient level, so we were unable to determine whether our data contained a large number of antibiotic prescriptions for a few patients or a few antibiotics for a large number of patients. Similarly, because our analysis was limited to prescription counts, we did not evaluate differences in antibiotic prescription dose or duration of therapy in this analysis. Sixth, we did not compare influenza-like illness and antiviral prescription rates in our study. Although this would have been a nice additional evaluation, these are typically evaluated weekly (rather than monthly) and span calendar years, making comparisons using our data challenging. Additional analyses should be performed to more rigorously evaluate the relationships among antiviral prescriptions, influenza-like illnesses, and antibiotic prescriptions.

In conclusion, there were no appreciable changes in overall antibiotic use over the 3-year study period in our cohort of more than 30 million privately insured individuals in the United States, despite the concurrent release of a number of guideline-based best practices designed to reduce inappropriate antibiotic consumption. Furthermore, we identified significant seasonal variation in antibiotic prescribing. Certain agents frequently associated with inappropriate management of upper respiratory tract infections, such as azithromycin, were prescribed at a higher rate during the winter months. Additional work is needed to better link antibiotic prescriptions to indications to better quantify and trend inappropriate antibiotic prescribing practices. However, in our opinion, additional interventions, beyond guidelines and educational materials, will be required to substantially improve antibiotic prescribing at a national level.

Acknowledgments

The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention or the National Institutes of Health.

Financial support: Research reported in this publication was supported by the Centers for Disease Control and Prevention epicenters program (grant no. U54CK000482) and the National Center for Advancing Translational Sciences of the National Institutes of Health (grant no. KL2TR000236).

Potential conflicts of interest: M.J.D. has created continuing educational materials for Medscape. Funding for those materials was provided to Medscape through an unrestricted educational grant from Merck. V.J.F. owns stock in Express Scripts Holding Company. K.D.M. and R.R.H. are employed by Express Scripts Holding Company and hold stocks in the company. All other authors report no conflicts of interest.

Address correspondence to Michael J. Durkin MD, MPH, Washington University School of Medicine, Campus Box 8051, 4523 Clayton Ave, St. Louis, MO, 63110 (mdurkin@wustl.edu).

References
